Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Selective Serotonin Reuptake Inhibitor Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

NCT06704594
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Interventions
sertraline 50 mg daily, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 2 Interventional

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

NCT00249405
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Citalopram + MI, Placebo + MI
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 4 Interventional Results available

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

NCT01148979
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lisdexamfetamine Dimesylate (Vyvanse), Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

NCT00735670
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Venlafaxine HCl, Placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression

NCT03222570
View directory record Official record
Conditions
Depressive Disorder
Interventions
Interpersonal Psychotherapy for Depressed Adolescents, Selective Serotonin Reuptake Inhibitor, Usual Care
Behavioral · Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Not applicable Interventional

Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury

NCT00167856
View directory record Official record
Conditions
Neuropathic Pain, Pain, Spinal Cord Injuries
Interventions
Venalafaxine hydrochloride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Citalopram to Enhance Cognition in HD

NCT00271596
View directory record Official record
Conditions
Huntington Disease, Chorea, Executive Dysfunction
Interventions
20mg daily citalopram, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 4 Interventional Results available

Contact: Developing New Clinical Management Strategies

NCT03812588
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05455684
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
46
States / cities
Tucson, Arizona • Anaheim, California • Culver City, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 4 Interventional

Predicting Treatment Response in Patients With OCD

NCT03993535
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
selective serotonin reuptake inhibitor
Drug
Lead sponsor
University of Sao Paulo
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

NCT01045083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, escitalopram, methylphenidate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

NCT01263223
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 27, 2026, 2:37 AM EDT
Withdrawn No phase listed Observational

SSRI's and the Rate of Progression From MCI to Dementia

NCT04901494
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer Disease
Interventions
SSRI
Drug
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older
Timeline
2021 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01152554
View directory record Official record
Conditions
Major Depressive Disorder, MDD, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
93
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 4 Interventional Results available

Combining Medications to Enhance Depression Outcomes

NCT00590863
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

NCT02891278
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sertraline, Cytosine arabinoside, allogeneic stem cell transplantation
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

NCT02358343
View directory record Official record
Conditions
Depression, End Stage Renal Disease
Interventions
Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 27, 2026, 2:37 AM EDT
Terminated Phase 4 Interventional

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

NCT01856127
View directory record Official record
Conditions
Sexual Dysfunction, Major Depressive Disorder
Interventions
Vilazodone, Sertraline
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 27, 2026, 2:37 AM EDT
Suspended Phase 3 Interventional

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer

NCT04973930
View directory record Official record
Conditions
Major Depressive Disorder, Breast Cancer, Venlafaxine
Interventions
Interpersonal Psychotherapy, Venlafaxine HCl ER
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Not applicable Interventional

Depression and Self-care in Heart Failure

NCT01028625
View directory record Official record
Conditions
Heart Failure, Depression
Interventions
Cognitive Behavior Therapy, Heart Failure Self-care Education
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Sep 27, 2026, 2:37 AM EDT
Completed Phase 2 Interventional

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

NCT04497168
View directory record Official record
Conditions
Parkinson Disease
Interventions
Citalopram 20mg, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 27, 2026, 2:37 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression

NCT01579942
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 27, 2026, 2:37 AM EDT
Terminated Phase 2 Interventional Results available

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

NCT01103180
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 27, 2026, 2:37 AM EDT
Completed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials, Relapse Study

NCT04933630
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 27, 2026, 2:37 AM EDT